ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

TCDA Tricida Inc

0.108
0.00 (0.00%)
16 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Tricida Inc NASDAQ:TCDA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.108 0.104 0.105 0 01:00:00

Tricida to Report First Quarter Financial Results and Host Conference Call and Webcast on Thursday, May 6, 2021

27/04/2021 4:32pm

GlobeNewswire Inc.


Tricida (NASDAQ:TCDA)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Tricida Charts.

Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2021 financial results after the close of market on Thursday, May 6, 2021. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its first quarter financial results and business progress. The call or webcast may be accessed as follows:

Tricida Conference Call Information

Tricida will host its First Quarter Financial Results and Business Update Conference Call and webcast on Thursday, May 6, 2021 at 4:30 pm Eastern Time. The call or webcast may be accessed as follows:

Tricida Conference CallThursday, May 6, 20214:30 pm Eastern Time  
 
 Webcast:Dial-In:International:Conference ID:IR.Tricida.com(877) 377-5478(629) 228-07409047649 

A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.Tricida.com.

Contact: Jackie CossmonTricida, Inc.Senior Vice President of Investor Relations and CommunicationsIR@Tricida.com

Source: Tricida, Inc.

1 Year Tricida Chart

1 Year Tricida Chart

1 Month Tricida Chart

1 Month Tricida Chart

Your Recent History

Delayed Upgrade Clock